Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

“Jami is an industry-leading intellect and advisor to transformational healthcare companies,” said Mark Van Lith, CEO of Guggenheim Securities. “Jami is an important addition to our premier healthcare ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Cytrellis Biosystems, Inc., a pioneer in novel medical aesthetic solutions, today announced the launch of the updated ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...